Medicine and Dentistry
Uterine Cancer
100%
Recurrent Disease
84%
Diseases
79%
Ovarian Cancer
67%
Neoplasm
51%
Cancer
48%
Cervical Cancer
45%
Conservative Treatment
37%
Ovarian Tumor
36%
Sentinel Lymph Node
36%
Krukenberg Tumor
35%
Fertility Preservation
27%
Overall Survival
25%
Cystectomy
24%
Progression Free Survival
24%
DNA Mismatch Repair
24%
Adjuvant Therapy
23%
Cohort Analysis
22%
Endometrium Carcinoma
19%
Hazard Ratio
19%
Gene Repair
18%
Aromatase Inhibitor
18%
Cancer Risk
18%
Lymph Node
18%
BRCA1
18%
Cervicectomy
18%
Granulosa Cell Tumour
18%
Immature Teratoma
18%
Lenvatinib
18%
Pembrolizumab
18%
Pelvis
18%
Hysterectomy
16%
Proteomics
15%
In Vitro Fertilisation
14%
Gestagen
13%
CA-125
13%
BRCA2
13%
Fallopian Tube
12%
Ovulation Induction
12%
Gynecology
12%
Adjuvant Radiotherapy
12%
Symptomatic Treatment
12%
Gestational Age
12%
Proportional Hazards Model
12%
Mortality Rate
11%
Small for Gestational Age
11%
Therapy Delay
11%
Radical Hysterectomy
11%
Ovariectomy
10%
BRCA Mutation
10%
Keyphrases
Endometrial Cancer
61%
Chemotherapy
54%
Ovarian Cancer
53%
Borderline Ovarian Tumor
36%
Sentinel Lymph Node
36%
Cervical Cancer
33%
Fertility Preservation
31%
Fertility Sparing
30%
Tumor
29%
Cystectomy
26%
Epithelial Ovarian Cancer
26%
Adjuvant Therapy
24%
Conservative Management
24%
Overall Survival
21%
Gynecologic Malignancies
21%
Progression-free Survival
20%
Young Patients
19%
Recurrent Endometrial Cancer
19%
Recurrence Rate
19%
Mismatch Repair Genes
18%
Preterm Infants
18%
MLH1
18%
Aromatase Inhibitors
18%
BRCA mutation
18%
BRCA mutation Carriers
18%
Radical Vaginal Trachelectomy
18%
Early-stage Cervical Cancer
18%
Low-risk Endometrial Cancer
18%
Ovarian Cancer Patients
17%
Clinical Outcomes
17%
Cancer Patients
17%
In Vitro Fertilization Treatment
16%
Endometrial Adenocarcinoma
16%
Hysterectomy
16%
Confidence Interval
16%
Neonatal Outcome
15%
High-grade Ovarian Cancer
15%
Non-associated
15%
CA-125 Levels
15%
Live Birth
14%
Treatment Delay
14%
Liquid Biopsy
14%
Germline BRCA mutation
14%
Progestin
13%
Granular Cell Tumor
13%
Ovarian Malignancy
13%
Early Endometrial Cancer
13%
Adjuvant Radiotherapy
13%
Lenvatinib
13%
Pembrolizumab
13%